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Abstract Early diagnosis of spondyloarthritis (SpA) is
essential as anti-tumor necrosis factor therapy can achieve
significant symptomatic relief and control of disease activity.
Thisstudyaimstocomparetheclinicalcharacteristics,disease
activity, and functional status of a Chinese cohort of SpA
patients who were re-classified into ankylosing spondylitis
(AS) patients fulfilling the modified New York (MNY)
criteria, those with undifferentiated SpA (USpA) fulfilling
the European Spondyloarthropathy Study Group (ESSG)
classification criteria only (USpA/ESSG) and those who
fulfill Assessment of SpondyloArthritis International Society
(ASAS) only (USpA/ASAS). Disease activity was evaluated
by Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), severity of morning stiffness, patient global
assessment, and C-reactive protein. Functional status was
evaluated by Bath Ankylosing Spondylitis Functional Index
(BASFI), modified Schober index, and dimension of chest
expansion. One hundred and twenty-eight patients with
disease duration of 16.3±10.4 years were recruited. Patients
in USpA/ESSG and USpA/ASAS were significantly younger
(p=0.01), had shorter disease duration (p<0.01), and lower
BASFI (p=0.03) than established AS patients. All three
groups have active disease with comparable BASDAI >3.
BASFI correlated inversely with dimension of chest expan-
sion and negatively modified Schober index in AS patients
(p<0.01) and modestly with BASDAI (r=0.25, p<0.01).
BASFI correlated moderately with BASDAI in USpA/ESSG
(r=0.61, p<0.01) but not with chest expansion or modified
Schober index. Compared with established AS patients
recognized by MNY criteria, patients fulfilling USpA
defined by ESSG or ASAS criteria had earlier disease, as
active disease and less irreversible functional deficit.
Keywords Classification criteria.Disease activity.
Functional status.Spondyloarthropathy
Introduction
Spondyloarthritis (SpA) describes a spectrum of chronic
inflammatory spinal diseases characterized by progressive
spinal deformity and impaired mobility. The spectrum is
represented by undifferentiated SpA (USpA) on one end,
where there are minimal symptoms and changes on plain
radiography and by ankylosing spondylitis (AS) with
established radiological sacroiliitis on the other end.
Chronic inflammatory low back pain and radiographic
changes involving the sacroiliac (SI) joints are key
diagnostic features for AS according to the modified New
York (MNY) criteria established in 1984 [1]. Although the
MNY criteria have been widely used in both clinical and
research settings, the criteria are not sensitive enough to
identify patients with early disease as radiological changes
on plain X-ray are only apparent a number of years after
onset of spinal symptoms and often represents structural
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DOI 10.1007/s10067-011-1693-6damage in advanced disease [2]. Around 50% of SpA
patients are characterized by extra-spinal features [3]t h a t
form the basis for the European Spondyloarthropathy
Study Group (ESSG) classification criteria established in
1990 [4], which have higher sensitivity of diagnosis of
USpA. The ESSG criteria do not require presence of
radiological features, the sensitivity can be affected by the
prevalence of SpA in the locality and the number of
associated features and are thus deficient in the diagnosis
of axial SpA [5, 6]. HLA-B27 serotyping and magnetic
resonance imaging (MRI) scan of the SI joints are
nowadays recommended to assist early diagnosis of axial
SpA in patients with inflammatory back pain who lack
radiographic sacoiliitis [7].
There is a compelling need for early diagnosis of
patients with SpA as biologic therapy against tumor
necrosis factor-alpha (TNF-α) has been shown to achieve
significant improvement in symptoms and control of
disease activity in these patients [8, 9]. The Assessment of
SpondyloArthritis International Society (ASAS) has vali-
dated a newly developed classification criteria in June 2009
incorporating the use of Human Leucocyte Antigen-B27
(HLA-B27) serotyping and MRI features of early sacroilii-
tis to identify early axial SpA patients [10]. The ASAS
criteria have not been validated in patients of Chinese
ethnicity. Our study aimed to examine a local cohort of
SpA patients, including those with definite and possible
SpA, previously diagnosed by rheumatologists before the
establishment of ASAS criteria. These patients were re-
classified according to the MNY, ESSG, and ASAS
classification criteria into three groups, namely: (1) patients
fulfilling the MNY criteria, i.e., AS patients; (2) USpA
patients defined according to the ESSG criteria only
(USpA/ESSG); and (3) USpA patients fulfilling the ASAS
classification criteria only (USpA/ASAS). The clinical
characteristics of these three groups of patients in terms of
their demographic features, disease activity, and functional
status were compared.
Patients and methods
This study adopted a prospective cross-sectional design.
Clinical, laboratory, and plain radiological assessments on
the recruited subjects were performed on the same day at
the clinic visit. Further investigations, including HLA-B27
serotyping and MRI sacroiliac joints, were arranged within
4 weeks for those subjects who did not show definite
sacroiliitis on plain X-ray. The study was approved by the
ethics committee of the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong
West Cluster and conducted in accordance with the
Declaration of Helsinki. Consecutive patients of Southern
Chinese ethnicity were recruited from the university-
affiliated rheumatology clinic with informed consent. These
patients had been diagnosed to have definite or possible
SpA according to rheumatologist opinion before the
introduction of the ASAS criteria in 2009. Medical history
and physical examination were conducted by the same
rheumatologist (HYC) at the clinic visit. Patients who were
currently or previously treated with biological agents were
excluded. Demographic data including age, sex, disease
duration, onset of symptoms, symptomatology, including
the presence of inflammatory back pain, enthesitis, uveitis,
aortic regurgitation, dactylitis, psoriasis, inflammatory
bowel disease, urethritis, cervicitis, or acute diarrhea within
the month preceding onset of arthritis, family history of
SpA, current and previous treatment including disease
modifying anti-rheumatic drugs (DMARDs), and non-
steroidal anti-inflammatory drugs (NSAIDs) were retrieved
from medical records and verified with patients at the clinic
visit. Inflammatory back pain was defined by the presence
of at least two of the following features: morning stiffness
of >30 min, improvement with exercise but not with rest,
awakening because of back pain during the second half of
night, and alternating buttock pain [11]. Patients who had a
history of acute-onset diarrhea within the month before
arthritis onset and psoriasis, inflammatory bowel disease,
urethritis, or cervicitis, and those currently or previously on
biologic agents were excluded from the study.
Disease activity and functional ability in these patients
were examined using the Chinese version of Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI) [12–
14] and the Bath Ankylosing Spondylitis Functional Index
(BASFI) [15]. Severity of morning stiffness was determined
by calculating the average score of questions 5 and 6 of
BASDAI. Patient Global Assessment (PGA) was scored on
a ten-point visual analogue scale (VAS). The BASDAI,
BASDFI, and PGA score ranged from 0 to 10. Physical
examination was performed to determine spinal mobility
including lumbar flexion [modified Schober index (MSI)]
and chest expansion. Enthesitis was defined by tenderness
on palpation over the insertions of the Achilles tendon or
the plantar fascia. Peripheral arthritis was defined by
warmth, swelling, or tenderness of the extra-spinal joints.
Blood investigations including complete blood picture,
liver and renal function tests, and C-reactive protein
(CRP) were measured. All subjects had radiographs of the
SI joints, and the stages of sacroiliitis were graded
according to MNY criteria. Chest x-ray was taken to
examine for presence of upper lobe pulmonary fibrosis.
Echocardiogram was performed to examine for valvular
heart lesion if cardiac murmur was detected on auscul-
tation. Radiographs of the symptomatic peripheral joints
were taken to detect joint erosion. Contrast MRI scan of
the SI joints and HLA B27 typing were arranged for
948 Clin Rheumatol (2011) 30:947–953subjects who did not show radiographic changes of grade
2 or above on plain x-ray of the SI joints. All
radiographs and MRI images were interpreted by the
same radiologist (KPW).
These patients were then evaluated for their fulfillment
of one or more of the three classification criteria: the MNY,
ESSG, and ASAS classification criteria. The three groups
of patients were then selected for comparison on their
demographic and clinical features, disease activity, and
functional status. Patients were reclassified into AS group if
they fulfilled the MNY criteria, the “USpA defined by
ESSG criteria” (USpA/ESSG) group if they fulfilled the
ESSG criteria but not the MNY criteria and the “USpA
defined by ASAS criteria only” (USpA/ASAS) group if
they fulfilled the ASAS criteria but not the MNY or ESSG
classification criteria.
Statistical analysis
Statistical analysis was performed by SPSS 16.0 (Chicago,
USA). Continuous data was expressed as mean±standard
deviation (SD) and categorical variables as counts and
percentages. One-way ANOVA was used to compare
parametric variables between groups. Mann–Whitney U
test was used for comparison of non-parametric data.
Spearman's rank correlation was performed to determine
correlation between different non-normally distributed
variables. P value of <0.05 was considered statistically
significant in this study.
Results
One hundred and twenty eight consecutive Chinese
patients with prior diagnosis of SpA were recruited.
These included 92 male and 36 female patients. The
mean±SD age of these patients were 43.8±13.7 years
with disease duration of 16.3±10.4 years. One hundred
and seventeen patients (91.4%) had inflammatory back
pain at disease onset or during the disease course.
Ninety-two patients (71.9%) fulfilled the MNY criteria,
whereas 107 (83.6%) fulfilled the ESSG criteria and 126
(98.4%) fulfilled the ASAS classification criteria for
axial SpA. Eighteen patients (14.1%) met the ESSG but
not the MNY criteria and were reclassified into the
USpA/ESSG group. Another 18 patients (14.1%) fulfilled
the ASAS but not ESSG criteria for axial SpA and were
reclassified into the USpA/ASAS group. Among these
patients, 15 (83.3%) had MRI features suggestive of
early sacroiliitis, whereas HLA-B27 positivity was found
in the remaining patients. Figure 1 shows reclassification
of patients in our cohort into these three groups for
subsequent comparison.
Demographic and clinical features
Table 1 showsthedemographicandclinicalfeaturesofpatients
reclassified into the AS, USpA/ESSG, and USpA/ASAS
groups. AS patients were significantly older (p=0.01 by
ANOVA) and had longer disease duration (p<0.01) compared
to patients in the other groups. The USpA/ASAS group
tended to be younger (37.4±6.4 vs 38.3±5.2 years; p=0.83)
and had shorter disease duration (9.2±2.3 vs 11.6±3.8 years,
p=0.25) compared to the USpA/ESSG group, but the
difference was not statistically significant. The prevalence of
extra-spinal features including uveitis [16], upper lobe fibrosis
[17–19], aortic regurgitation [20, 21], dactylitis, peripheral
arthritis, and peripheral joint erosion were similar among the
three groups and were comparable to those reported in
Caucasian populations in the literature. Enthesitis (27.8%)
was a more frequent complaint in the USpA/ESSG group [22]
compared to AS patients (7.6%) and the USpA/ASAS group
(5.6%) (p=0.01). The use of medications, including NSAIDs
and sulphasalazine, was not different between these groups.
Disease activity and functional status
Parameters of disease activity and functional status of the
three groups are summarized in Table 2. BASDAI in AS,
USpA/ESSG, and USpA/ASAS groups were 4.1±0.4, 4.1±
1.1, and 3.5±0.9 respectively. BASDAI (p=0.42), severity
of morning stiffness (p=0.36), and CRP levels (p=0.23)
128 spondyloarthritis patients 
diagnosed previously by 
rheumatologists before establishment 
of ASAS classification criteria 
Assessment for fulfillment of the MNY criteria, ESSG and 
ASAS classification criteria 
(AS group) 
The “AS” group 
fulfilled the MNY 
criteria 
(n=92)
(USpA/ESSG)
The “ESSG defined 
USpA” group 
fulfilled ESSG but 
not MNY criteria 
(n=18) 
(USpA/ASAS) 
The “USpA defined 
ASAS” group  
fulfilled ASAS but not 
ESSG criteria 
(n=18) 
Fig. 1 Reclassification of spondyloarthritis patients according to the
MNY criteria, ESSG and ASAS classification criteria
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global assessment score were recorded among AS patients
(4.7±0.4) compared to the USpA/ESSG (4.1±0.8) and USpA/
ASAS (3.6±0.9) groups (p=0.03). AS patients also had the
highest BASFI (p=0.03), lowest dimension of chest expan-
sion (p=0.01), and lowest modified Schober index (p<0.01)
among patients in these groups. There was no difference in
BASFI (p=0.60), chest expansion (p=1.00), and modified
Schober index (p=1.00) between the USpA/ESSG and USpA/
ASAS patients.
CorrelationsbetweenfunctionalstatusreflectedbyBASFI,
disease activity by BASDAI, and disease damage by chest
expansion and the modified Schober index were determined
in the three SpA groups (Table 3). Among AS patients,
BASFI was found to correlate weakly with BASDAI
(r=0.25, p<0.01), and negatively with dimension of chest
expansion (r=−0.28; p<0.01) and the modified Schober
index (r=−0.38; p<.01). In the USpA/ESSG group, BASFI
correlated moderately with BASDAI (r=0.61, p<0.01)
alone. BASFI in the USpA/ASAS group showed no
correlation with BASDAI, chest expansion, and the modified
Schober index. Figure 2 shows the contribution of BASDAI
e x p r e s s e da saf u n c t i o no fB A S D A I / B A S F Ic o m p l e xr e p r e -
senting reversible and “relative” irreversible elements in the
three SpA groups. Disease activity reflected by BASDAI
accounted for 56.2%, 68.3%, and 74.5% in AS patients, the
USpA/ESSG, and USpA/ASAS groups, respectively.
Discussion
Our study demonstrated distinct clinical features of USpA
patients classified by the ESSG or ASAS classification
criteria compared to AS patients defined by the MNY
criteria. The ASAS criteria demonstrated highest sensitivity
(98.4%) compared to the MNY (71.9%) and the ESSG
(83.6%) criteria in our SpA cohort. A lower sensitivity for
MNY criteria (39.6%) but similar sensitivity by ESSG
criteria (87%) was reported in other cohorts of different
ethnicities [23–26]. Around 5% of patients presented with
chronic inflammatory back pain at the primary care have
been found to have underlying SpA [27]. Inflammatory
Table 1 The demographic and clinical manifestations of patients in the three reclassified SpA groups
AS group USpA/ESSG group USpA/ASAS group P value Caucasian series (30–36)
Age (years) 45.7±2.9 38.3±5.2 37.4±6.4 0.01
Male gender 67 (72.8%) 10 (55.6%) 15 (83.3%) 0.17
Disease duration (years) 18.7±2.2 11.6±3.8 9.2±2.3 <0.01
Clinical features
Uveitis 45 (48.9%) 5 (27.8%) 7 (38.9%) 0.22 25–40% [16]
Upper lobe fibrosis 18 (19.6%) 3 (16.7%) 0 (0.0%) 0.12 1.3–30% [17–19]
Aortic regurgitation 3 (3.3%) 1 (5.6%) 0 (0.0%) 0.63 2–12% [20, 21]
Dactylitis 12 (13.0%) 1 (5.6%) 1(5.6%) 0.48 N/A
Enthesitis 7 (7.6%) 5 (27.8%) 1(5.6%) 0.01 22–27% [22]
Peripheral arthritis 41 (44.6%) 9 (50%) 7(38.9%) 0.80 N/A
Joints erosion 4 (4.3%) 0 (0.0%) 0(0.0%) 0.45 N/A
Medications
NSAID 77 (83.7%) 15 (83.3%) 16 (88.9%) 0.19
Sulphalazine 49 (53.3%) 11 (61.1%) 8 (44.4%) 0.98
N/A not available
Disease activity AS group USpA /ESSG group USpA/ASAS group P value
BASDAI 4.1±0.4 4.1±1.1 3.5±0.9 0.42
Severity of morning stiffness 3.6±0.5 3.1±1.2 2.8±1.0 0.36
Patient global assessment 4.7±0.4 4.1±0.8 3.6±0.9 0.03
CRP 1.4±0.5 0.5±0.5 0.9±0.8 0.23
Functional status
BASFI 3.2±0.6 1.9±1.0 1.2±0.7 0.03
Chest expansion (cm) 3.5±0.3 4.6±0.6 4.8±0.8 0.01
Modified Schober test (cm) 1.9±0.3 3.7±0.7 3.6±0.6 <0.01
Table 2 Disease activity and
functional status of patients in
the three reclassified SpA
groups
950 Clin Rheumatol (2011) 30:947–953back pain was reported by 93.7% of our patients, which is a
key feature to most diagnostic criteria including the MNY
and ASAS criteria. The presence of chronic inflammatory
back pain has been shown to increase the positive
likelihood ratio by 12-fold in the screening for SpA [11].
The ASAS and ESSG classification criteria have been
developed aiming to encompass patients with USpA.
Indeed, both sets of classification criteria were found to
characterize SpA patients at an earlier stage who were
younger and had shorter disease duration compared to the
MNY criteria in our cohort. The ESSG involves extra-
spinal features as inclusion criteria, whereas the ASAS
criteria involves MRI scan of the SI joints and HLA-B27
serotyping early in the diagnostic algorithm. MRI scan has
been proven clinically useful in the management of SpA
patients as it can detect early inflammatory changes in the
SI joints to facilitate early diagnosis [28] and can reflect
extent of spinal inflammation that has been shown to be a
predictive factor of clinical response to anti-TNF therapy
[29]. HLA-B27 serotyping, in addition to inflammatory
back pain in the primary care setting, has been found to be
the best measure to predict future development into AS
[30]. Serum level of CRP was not different between these
patients and had not been regarded as a satisfactory marker
in the assessment of disease activity [31]. BASDAI of
patients in these groups were above three, suggestive of
active disease and was not different in level between USpA
subjects and established AS patients. Thus, many of these
patients who had early or late disease were indicated for
anti-TNF therapy according to the ASAS recommendation
[32, 33].
USpA patients recognized by the ASAS criteria were
found to have the lowest BASFI revealing better functional
status than the other groups. Recent studies showed that
spinal mobility impairment is contributed by both spinal
inflammation, as a reversible element, and irreversible
spinal damage [34]. The better dimension of chest
expansion and modified Schober index demonstrated by
USpA patients recognized by ESSG and ASAS criteria
may, thus, suggest that these patients had less irreversible
damage. BASFI was found to correlate weakly with
BASDAI and negatively with chest expansion and the
modified Schober index in AS patients, suggesting both
reversible and irreversible components contributing to
worse functional status in established SpA. On the other
hand, BASDAI was the only feature that correlated with
BASFI in USpA patients recognized by ESSG criteria
suggesting predominant contribution of functional status
from reversible component that may be amendable to
treatment and disease control. Thus, both ASAS and ESSG
criteria appeared to identify USpA early before clinically
significant chronic damage was apparent. Although we
were not able to show significant difference in clinical
characteristics between USpA defined by ESSG and ASAS
criteria because of our small sample size, the ASAS criteria
is expected to be more sensitive for diagnosing USpA
including those patients who did not fulfill the ESSG
criteria by incorporating MRI of the SI joints and HLA-B27
serotyping.
Around 59–68% USpA patients have been reported to
evolve progressively into established AS over 10 years [35,
36]. Although it remains controversial whether anti-TNF
therapy in SpA will lead to retardation of disease
progression [37–39], recognition of USpA early in the
Correlation coefficient with BASFI AS group USpA/ESSG group USpA/ASAS group
BASDAI 0.25 0.61 0.48
P value <0.01 <0.01 0.73
Modified Schober index −0.38 −1.27 −0.08
P value <0.01 0.22 0.82
Chest expansion −0.28 −1.62 −0.17
P value <0.01 0.13 0.63
Table 3 Correlations between
BASFI and BASDAI and spinal
mobility in the three reclassified
SpA groups
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
BASDAI
BASFI
AS group USpA/ESSG USpA/ASAS 
(n=92) (n=18) (n=18) 
56.2% 68.3% 74.5%
Fig. 2 The proportion of BASDAI in the BASDAI/BASFI complex
representing reversible and “relative” irreversible elements in the three
reclassified SpA groups
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TNF blockers can offer significant symptomatic control,
amelioration of disease activity, and improved quality of
life [40–43]. Indeed, USpA patients who fulfill ESSG or
ASAS criteria in our cohort demonstrated a number of
clinical features that have been recognized to be predictors
of better response to TNF blockers including shorter
disease duration, lower BASFI, younger age, as well as
raised ESR or CRP [44]. Thus, early treatment for better
symptomatic relief and disease control is warranted in these
patients with early disease.
This study is limited by the predominance of patients
with established AS in our cohort. The small sample size of
patients with USpA and early disease limited the statistical
power to examine for any discriminative clinical character-
istics between the ESSG and ASAS groups. We demon-
strated highest sensitivity of diagnosis of SpA patients by
the ASAS criteria among existing classification criteria. We
showed that USpA patients had early disease with more
reversible element to contribute to their functional status.
With the availability of more efficacious treatment, early
diagnosis can allow earlier symptom control, alleviation of
disease activity, and hopefully, prevention of irreversible
damage in patients with SpA.
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